Tolcapone: an efficacy and safety review (2007)
C Warren Olanow1, Paul B Watkins
1Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, USA. warren.olanow@mssm.edu
Clinical Neuropharmacology
|October 3, 2007
Summary
Tolcapone effectively treats Parkinson disease motor fluctuations. Despite rare severe liver injury risks, recent data show it is a safe and valuable treatment option with careful monitoring.
Area of Science:
- Pharmacology
- Neurology
- Hepatology
Background:
- Tolcapone is a catechol-O-methyltransferase inhibitor used for Parkinson disease.
- It effectively reduces motor fluctuations and levodopa needs in patients with Parkinson disease.
- Concerns regarding hepatotoxicity led to market withdrawal and restrictions.
Purpose of the Study:
- To review the safety and efficacy data of tolcapone.
- To assess the risk of severe liver injury associated with tolcapone treatment.
- To inform current clinical practice and monitoring guidelines.
Main Methods:
- Analysis of clinical trial data and postmarketing surveillance reports.
- Review of safety data following 1998 labeling restrictions.
- Examination of updated Food and Drug Administration monitoring requirements.
Main Results:
- Tolcapone significantly reduces "off" time and levodopa requirements.
- Severe liver injury is a rare event, with few reported cases and no fatalities since 1998.
- Post-restriction data show over 40,000 patient-years of treatment with minimal severe liver events.
Conclusions:
- Severe liver injury from tolcapone is rare.
- Tolcapone remains an effective adjunct therapy for Parkinson disease.
- Current monitoring guidelines balance efficacy with safety, allowing for its reintroduction and continued use.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:00Drug Toxicity: Overview
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...